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Modulation of pathogen-induced CCL20 secretion from HT-29
human intestinal epithelial cells by commensal bacteria
Abstract
BACKGROUND: Human intestinal epithelial cells (IECs) secrete the chemokine CCL20 in response to
infection by various enteropathogenic bacteria or exposure to bacterial flagellin. CCL20 recruits
immature dendritic cells and lymphocytes to target sites. Here we investigated IEC responses to various
pathogenic and commensal bacteria as well as the modulatory effects of commensal bacteria on
pathogen-induced CCL20 secretion. HT-29 human IECs were incubated with commensal bacteria
(Bifidobacterium infantis or Lactobacillus salivarius), or with Salmonella typhimurium, its flagellin,
Clostridium difficile, Mycobacterium paratuberculosis, or Mycobacterium smegmatis for varying times.
In some studies, HT-29 cells were pre-treated with a commensal strain for 2 hr prior to infection or
flagellin stimulation. CCL20 and interleukin (IL)-8 secretion and nuclear factor (NF)-kappaB activation
were measured using enzyme-linked immunosorbent assays. RESULTS: Compared to untreated cells, S.
typhimurium, C. difficile, M. paratuberculosis, and flagellin activated NF-kappaB and stimulated
significant secretion of CCL20 and IL-8 by HT-29 cells. Conversely, B. infantis, L. salivarius or M.
smegmatis did not activate NF-kappaB or augment CCL20 or IL-8 production. Treatment with B.
infantis, but not L. salivarius, dose-dependently inhibited the baseline secretion of CCL20. In cells
pre-treated with B. infantis, C. difficile-, S. typhimurium-, and flagellin-induced CCL20 were
significantly attenuated. B. infantis did not limit M. Paratuberculosis-induced CCL20 secretion.
CONCLUSION: This study is the first to demonstrate that a commensal strain can attenuate CCL20
secretion in HT-29 IECs. Collectively, the data indicate that M. paratuberculosis may mediate mucosal
damage and that B. infantis can exert immunomodulatory effects on IECs that mediate host responses to
flagellin and flagellated enteric pathogens.
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Abstract
Background: Human intestinal epithelial cells (IECs) secrete the chemokine CCL20 in response
to infection by various enteropathogenic bacteria or exposure to bacterial flagellin. CCL20 recruits
immature dendritic cells and lymphocytes to target sites. Here we investigated IEC responses to
various pathogenic and commensal bacteria as well as the modulatory effects of commensal
bacteria on pathogen-induced CCL20 secretion. HT-29 human IECs were incubated with
commensal bacteria (Bifidobacterium infantis or Lactobacillus salivarius), or with Salmonella
typhimurium, its flagellin, Clostridium difficile, Mycobacterium paratuberculosis, or Mycobacterium
smegmatis for varying times. In some studies, HT-29 cells were pre-treated with a commensal strain
for 2 hr prior to infection or flagellin stimulation. CCL20 and interleukin (IL)-8 secretion and
nuclear factor (NF)-κB activation were measured using enzyme-linked immunosorbent assays.
Results: Compared to untreated cells, S. typhimurium, C. difficile, M. paratuberculosis, and flagellin
activated NF-κB and stimulated significant secretion of CCL20 and IL-8 by HT-29 cells. Conversely,
B. infantis, L. salivarius or M. smegmatis did not activate NF-κB or augment CCL20 or IL-8
production. Treatment with B. infantis, but not L. salivarius, dose-dependently inhibited the baseline
secretion of CCL20. In cells pre-treated with B. infantis, C. difficile-, S. typhimurium-, and flagellin-
induced CCL20 were significantly attenuated. B. infantis did not limit M. Paratuberculosis-induced
CCL20 secretion.
Conclusion: This study is the first to demonstrate that a commensal strain can attenuate CCL20
secretion in HT-29 IECs. Collectively, the data indicate that M. paratuberculosis may mediate
mucosal damage and that B. infantis can exert immunomodulatory effects on IECs that mediate host
responses to flagellin and flagellated enteric pathogens.
Background
Intestinal epithelial cells (IECs) play a crucial role in the
maintenance of mucosal homeostasis, and actively sam-
ple commensal bacteria, pathogens, and other antigens
[1,2]. Under normal circumstances, the mucosal immune
system exhibits a restrained response to commensal bac-
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immune responses to pathogenic bacteria. IECs can trig-
ger innate immune responses that activate pro-inflamma-
tory signalling pathways, as well as direct the migration of
various effector cells involved in adaptive immunity [2].
Bone marrow-derived dendritic cells (DCs) in the lamina
propria also sample commensal and pathogenic bacteria
at mucosal interfaces [3,4]. This appears to be achieved by
opening tight junctions and extending dendrites between
IECs [5]. Encounter with bacteria or bacterial antigens
triggers the functional maturation of DCs leading to the
generation of antigen-presenting cells that can activate
naïve T cells [6]. Therefore, the recruitment of DCs into
the epithelium is a prerequisite for the initiation of adap-
tive immune responses.
Trafficking of leukocytes and DCs to a specific site is
dependent on chemokines [7]. Chemokines bind to and
activate members of G protein-coupled seven-transmem-
brane domain receptors that are differentially expressed
on leukocytes [8]. The chemokine CCL20 (also known as
macrophage inflammatory protein-3α, liver and acti-
vated-regulated chemokine, or Exodus-1) selectively
attracts effector and memory T lymphocytes, immature
DCs, and naïve B cells that express its specific receptor,
CCR6 [9]. CCL20 is expressed constitutively at immuno-
logical barriers such as the gastrointestinal tract and the
skin. The colonic epithelium has been demonstrated as a
major source of CCL20 and epithelial expression of this
chemokine is elevated in inflammatory bowel disease
[10]. The appendix, tonsils, and skin keratinocytes are
also significant producers of CCL20 [11-13]. CCL20
expression in IECs is increased by a variety of inflamma-
tory stimuli such as interleukin (IL)-1β, tumour necrosis
factor-α, and enteropathogenic bacteria including species
of Salmonella and Listeria [14-16]. It has been shown that
flagellin, the protein subunit of bacterial flagella, rather
than lipopolysaccharide or invasion, is the key Salmonella
virulence factor responsible for the induction of epithelial
CCL20 [16]. Recent studies found that CCL20 transcrip-
tion is upregulated by flagellin-Toll-like receptor 5 (TLR5)
signaling in the human intestinal epithelial cell lines: T84
and Caco-2 [16,17]. The constitutive and inducible
expression of CCL20 implicates an important role for
CCL20 both in gut homeostasis and in mucosal immune
responses to stress signals. CCL20 expression is upregu-
lated in a variety of inflammatory disorders including
appendicitis, atopic dermatitis, rheumatoid arthritis, and
inflammatory bowel diseases such as Crohn's disease [9].
This suggests that mucosal inflammation is associated
with altered leukocyte and DC trafficking.
Recent evidence supports the role of commensal bacteria
in maintaining immune homeostasis within the gut [18-
20]. Several strains of commensal bacteria can function-
ally modulate the epithelium by attenuating the secretion
of the neutrophil-recruiting chemokine IL-8 [19-23]. In
this study, we examined CCL20 production in response to
individual pathogenic and commensal bacteria and
whether commensal bacteria could restrain CCL20 secre-
tion specifically from HT-29 IECs. We demonstrate differ-
ential stimulation of CCL20 secretion from HT-29 cells
and an attenuation of both baseline and inducible CCL20
secretion by commensal bacteria. Collectively, the data
could indicate that certain commensal bacteria could con-
tribute to the maintenance of mucosal homeostasis by
restraining exaggerated inflammatory responses to the
antigenic burden within the gut.
Methods
Bacteria and growth conditions
The commensal strains used in this study, Bifidobacterium
infantis 35624 and Lactobacillus salivarius subspecies sali-
varius UCC118 [24,25], have been shown previously to
have probiotic properties [23,24,26,27]. The bacteria were
stored in 50% glycerol at -70°. Prior to use in experi-
ments, B. infantis was cultured anaerobically at 37° in de
Man Rogosa Sharpe (MRS) (Merck, Darmstadt, Germany)
broth supplemented with 0.05% cysteine (Sigma-Aldrich,
St. Louis, MO) for 48 hr, whereas L. salivarius was cultured
anaerobically at 37° in MRS broth for 18 hr. The station-
ary-phase bacteria were centrifuged and were resuspended
in sterile phosphate-buffered saline (PBS).
The flagellated enteropathogenic bacteria used in this
study were gram-negative Salmonella typhimurium UK1
and gram-positive Clostridium difficile ribotype 001. S.
typhimurium UK1 (kindly provided by R. Curtiss III, Wash-
ington University in St Louis, MO) was stored in 50%
glycerol at -70°. For experimental investigations, the bac-
teria were cultured at 37° in tryptic soy broth (Merck) for
18 hr under aerobic conditions.
Subsequently, the bacteria were centrifuged and resus-
pended in PBS. C. difficile 001 (kindly provided by J. Bra-
zier, Anaerobic Reference Laboratory, University Hospital
of Wales, Cardiff, UK) is a common cause of nosocomial
diarrhoea [28]. It produces exotoxins A and B that are pro-
inflammatory and enterotoxic in the human intestine
[29,30]. C. difficile was cultured at 37° under anaerobic
conditions in fastidious anaerobic broth (Lab M, Interna-
tional Diagnostics Group Plc, Bury, UK) for 48 hr, fol-
lowed by sub-culturing in fresh fastidious anaerobic broth
for a further 24 hr. Live C. difficile bacteria present in the
culture broth were used directly to infect HT-29 monolay-
ers.
Subsequently, cell-free supernatants were harvested by
centrifugation at 2500 g for 10 min. The supernatant was
carefully decanted through a 0.2 μm filter to remove anyPage 2 of 13
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the cell-free supernatant was confirmed by plating aliq-
uots of the cell-free supernatant onto Columbia blood
agar (Oxoid, Hampshire, UK).
Mycobacterium avium subspecies paratuberculosis
ATCC43109 (American Type Culture Collection, Manas-
sas, VA) was cultured in Middlebrook 7H9 broth (Difco
Laboratories, Detroit, MI) supplemented with 10% Mid-
dlebrook oleic acid/albumin/dextrose/catalase (OADC)
(Becton Dickinson, Franklin Lakes, NJ), 2 ml/l 80% glyc-
erol and 2 mg/ml mycobactin J (Allied Laboratories Inc.,
Synbiotics Europe) for 2 weeks at 37° in a shaking aerobic
incubator. Subsequently, the bacteria were subcultured
for a further month in Middlebrook 7H9 broth supple-
mented with OADC and mycobactin J. Mycobacterium
smegmatis mc(2) 155 (University College Cork Culture
Collection), a non-pathogenic mycobacteria that has been
used frequently as a tool in the study of mycobacterial
genetics [31], was grown similarly but without the addi-
tion of mycobactin J. Prior to use, the mycobacteria were
centrifuged and resuspended in PBS. The viability of the
mycobacteria cultures was tested routinely using Ziehl-
Nielssen acid-fast staining and culture purity was assessed
by streaking serial dilutions of the bacterial suspensions
on tryptic soy agar (TSA) (Merck). The appearance of any
colonies following 24 hr incubation at 37° indicated con-
tamination.
For all assays, bacteria were used in the stationary-phase
of growth and were Gram-stained or streaked on TSA (for
mycobacteria species) to confirm purity. Bacterial number
was estimated by measuring the absorbance at 600 nm,
and relating the absorbance value to a standard curve of
colony forming units (CFU) on MRS agar (Merck) (for B.
infantis and L. salivarius), TSA (for S. typhimurium),
Columbia blood agar (for C. difficile), or Middlebrook
agar (for M. paratuberculosis and M. smegmatis).
Epithelial cell culture
In this study, the HT-29 human colonic epithelial cell line
(American Type Culture Collection) was chosen because
this IEC has been used extensively by us and other groups
investigating epithelial responses to bacteria [21-
23,32,33]. HT-29 cells were cultured in modified McCoy's
5A medium (GIBCO-BRL, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal calf serum (FCS)
(Sigma) in the presence or absence of 100 U/ml penicillin
G and 100 μg/ml streptomycin (GIBCO-BRL). The cells
were routinely propagated in 75-cm2 tissue culture flasks
at 37° in a humidified, 5% CO2 incubator until they
approached 80-90% confluency. Subsequently, the cells
were trypsinized and used in experimental investigations
as specified below.
HT-29 cell treatments
For all assays, cell viability was determined by trypan blue
exclusion, and a known number of HT-29 cells were
seeded into 3.8-cm2 12-well plates and grown to conflu-
ence. Time and dose response studies were carried out as
part of the optimisation phase of this study (data not
shown). HT-29 cell-viability and pH changes were also
taken into account. Hence, for experiments, S. typhimu-
rium was used at 1 × 107 CFU/ml (MOI 10) for 6 hr given
optimal secretion of chemokines within this time. M.
paratuberculosis and M. smegmatis were used at 1 × 107
CFU/ml or 1 × 108 CFU/ml (MOI 10 and 100 respectively)
for 6 hr and 12 hr. A longer incubation period resulted in
impaired cell viability. C. difficile was used at 1 × 107 CFU/
ml (MOI 10) for up to 24 hr. Confluent monolayers were
also treated with 1 × 105, 1 × 106, or 1 × 107 CFU/ml live
commensal bacteria B. infantis or L. Salivarius for 6 hr. For-
malin-killed commensal bacteria, prepared as described
previously [34], were used to treat confluent HT-29 mon-
olayers at a dose equivalent to 1 × 107 CFU/ml. Dose
response studies were performed to determine the opti-
mal concentration of flagellin to use for stimulation of
IECs. Subsequently, HT-29 cells were treated with 0.5 μg/
ml purified S. typhimurium flagellin (InvivoGen Corp.,
San Diego, CA), a dose used by us in a previous study [23].
In some experiments, HT-29 cells were pre-treated for 2 hr
with or without a known dose of commensal bacteria.
Subsequently, the cells were incubated under aerobic con-
ditions with an equivalent dose of S. typhimurium, C. diff-
icile culture, an equivalent volume of C. difficile cell-free
supernatant, or with 1 × 108 CFU/ml mycobacteria, or
were treated with 0.5 μg/ml flagellin for varying times.
Modified McCoy's 5A medium supplemented with 10%
heat-inactivated fetal calf serum and 100 U/ml penicillin
G and 100 μg/ml streptomycin was used. Antibiotics were
useful in preventing contamination and maintaining a
bacteriostatic effect. The concentration (1 × 107 CFU/ml)
of S. typhimurium and C. difficile at the end-point of the co-
culture system was determined by streaking appropriate
agar plates. No bacterial growths, pH changes or impaired
cell-viability were recorded.
CCL20 Enzyme-linked immunosorbent assay
Confluent HT-29 cells grown in antibiotic- and serum-
supplemented media were treated for varying times with
known doses of bacteria or flagellin. Following treatment,
immunoreactive CCL20 protein levels in cell-culture
supernatants were quantified using an enzyme-linked
immunosorbent assay (ELISA) DuoSet kit (R&D Systems,
Minneapolis, MN) according to the manufacturer's proto-
col.
IL-8 ELISA
Immunoreactive IL-8 protein levels in cell-culture super-
natants of bacteria- or flagellin-treated HT-29 cells werePage 3 of 13
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according to the manufacturer's protocol.
Nuclear factor (NF)-κB p65 transcription factor assay
Confluent HT-29 monolayers were treated for 1 hr with
known doses of bacteria or flagellin. Nuclear proteins
were extracted using the Active Motif Nuclear Extract kit
(Active Motif Europe, Rixensart, Belgium) according to
the manufacturer's instructions, and the total protein con-
centration of the lysates was determined by Bradford assay
(Bio-Rad, Hercules, CA). Activation of the nuclear factor
(NF)-κB p65 subunit in 5 μg of HT-29 nuclear extracts was
determined using an NF-κB p65 ELISA-based transcrip-
tion factor assay kit (TransAM assay) (Active Motif
Europe) according to the manufacturer's protocol. The
NF-κB detecting antibody recognizes an epitope on p65
that is accessible only when NF-κB is activated. The posi-
tive control Jurkat nuclear extract provided with the kit
was used to assess assay specificity.
Statistics
All data are expressed as mean ± SE. Statistical analyses
were performed using unpaired two-tailed Student's t tests
or analysis of variance (ANOVA). P values < 0.05 were
considered to be statistically significant, and n represents
the number of independent experiments performed.
Results
HT-29 IECs respond differentially to commensal and 
pathogenic bacteria
ELISA was used to examine CCL20 and IL-8 protein secre-
tion from confluent HT-29 monolayers treated for 6 hr, 12
hr or 24 hr. HT-29 cells constitutively secreted CCL20, and
119.5 (± 26) pg/ml CCL20 were detected in cell culture
supernatants from untreated cells after 6 hr (Fig. 1). Com-
pared to untreated cells, infection with S. typhimurium (1
× 107 CFU/ml) or exposure to its flagellin stimulated sig-
nificant secretion of CCL20 within 6 hr. The levels of
CCL20 induced by S. typhimurium or flagellin were com-
parable. C. Difficile significantly stimulated CCL20 secre-
tion only after 24 hr incubation. (Fig. 1). The levels of
CCL20 induced by C. difficile bacteria (1 × 107 CFU/ml)
(1102 ± (64) pg/ml) and their cell-free supernatants
(1232 ± (67) pg/ml) were similar. Dose and time
response studies indicated that at a dose of 1 × 108 CFU/
ml M. paratuberculosis stimulated significant secretion of
CCL20 following 12 hr of infection. M. paratuberculosis
did not induce CCL20 release at lower doses or at earlier
time-points, and M. smegmatis did not stimulate CCL20
secretion at any of the doses or time-points tested. More-
over, the commensal bacteria (1 × 107 CFU/ml) did not
induce CCL20 release at any time-point tested (Fig. 1).
Previously, we have shown that flagellin and S. typhimu-
rium, but not B. Infantis or L. salivarius, significantly
induce IL-8 protein secretion from HT-29 cells [23]. In the
current study, we examined whether C. difficile and the
mycobacteria species used here stimulate IL-8 secretion
from HT-29 IECs. As shown in Fig. 2, infection with C. dif-
ficile bacteria and their cell-free supernatants significantly
stimulated IL-8 protein secretion after 24 hr incubation
but not at earlier time points. Exposure to 1 × 108 CFU/ml
M. paratuberculosis, but not M. smegmatis, significantly
stimulated IL-8 protein secretion after 12 hr compared to
untreated cells (2.78-fold increase). No significant IL-8
secretion was recorded at earlier time points and at lower
doses of M. paratuberculosis or M. smegmatis.
Bacterial-induced NF-κB DNA binding activity in HT-29 
IECs
Both CCL20 and IL-8 are transcriptionally regulated by
the transcription factor NF-κB [35,36]. In view of our find-
ing that HT-29 IECs respond differentially to various bac-
teria, and in particular, that M. paratuberculosis triggers
CCL20 and IL-8 secretion, we next examined NF-κB acti-
vation in bacterial-treated HT-29 cells. Exposure of HT-29
cells for 1 hr to S. typhimurium (1 × 107 CFU/ml), flagellin
(0.5 μg/ml), C. difficile (1 × 107 CFU/ml), or M. paratuber-
culosis (1 × 107 or 1 × 108 CFU/ml) augmented the DNA
binding activity of the p65 subunit of NF-κB compared
with untreated cells (Fig. 3). Although the levels of acti-
vated NF-κB detected in C. difficile and M. paratuberculosis-
infected cells were less than those detected in S. typhimu-
rium infected cells, they were significant nonetheless. NF-
κB DNA binding activity was detected in the positive con-
trol Jurkat nuclear extract, and the specificity of the NF-κB
binding in the assay was confirmed by competition with
free wild-type NF-κB consensus oligonucleotide or
mutated NF-κB oligonucleotide (Fig. 3). Together the data
demonstrate that HT-29 IECs respond differentially to
various antigens and, although M. paratuberculosis is not as
potent an immune activator as S. typhimurium, these
mycobacteria do trigger inflammatory responses.
B. infantis inhibits CCL20 secretion at baseline
In view of our previous finding that commensal bacteria
attenuate IL-8 secretion at baseline [23], we examined
whether treatment with increasing doses of B. infantis or
L. salivarius (1 × 105, 1 × 106, or 1 × 107 CFU/ml) affected
the baseline secretion of CCL20 by confluent HT-29 mon-
olayers. CCL20 protein levels were measured after 6 hr. In
cells treated with B. infantis, a dose-dependent inhibition
of baseline CCL20 secretion by confluent HT-29 monol-
ayers was observed (Fig. 4a). At a dose of 1 × 107 CFU/ml,
which under the experimental conditions was equivalent
to approximately 10 bacteria per epithelial cell, B. infantis
significantly inhibited basal CCL20 secretion by 24%.
Conversely, treatment with L. salivarius did not attenuate
baseline CCL20 secretion at any dose tested.Page 4 of 13
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tive CCL20 production was dependent on live B. infantis,
we examined the effect of formalin-killed bacteria on
CCL20 protein levels. Similar to live B. infantis, at a dose
equivalent to 1 × 107 CFU/ml formalin-killed B. infantis
significantly inhibited the baseline secretion of CCL20
(Fig. 4b). In contrast, neither live nor formalin-killed L.
salivarius affected the constitutive secretion of CCL20.
Together these data demonstrate that the ability of com-
mensal bacteria to restrain the baseline secretion of
CCL20 is species-specific and does not require live bacte-
ria.
B. infantis attenuates CCL20 induction by flagellated 
pathogenic bacteria
As shown in Fig. 5(a), infection of HT-29 monolayers with
S. typhimurium induced 8006 ± (1140) pg/ml CCL20 after
6 hr. Pre-treatment with live B. infantis limited S. typhimu-
rium-induced CCL20 secretion (P = 0.059), and pre-treat-
ment with formalin-killed B. infantis significantly
attenuated S. typhimurium-induced CCL20 production.
The modulation of S. typhimurium-stimulated CCL20 pro-
duction by commensal bacteria was strain-specific; L. sali-
varius did not dampen the IEC CCL20 response to S.
typhimurium.
Intestinal epithelial cells secrete CCL20 differentially in response to various bacteriaFigure 1
Intestinal epithelial cells secrete CCL20 differentially in response to various bacteria. Confluent HT-29 cells were 
treated with Salmonella typhimurium (1 × 107 colony-forming units (CFU)/ml), flagellin (0.5 μg/ml), Clostridium difficile (1 × 107 
CFU/ml), an equal volume of their cell-free culture supernatants, Mycobacterium paratuberculosis (1 × 108 CFU/ml), M. smegmatis 
(1 × 108 CFU/ml), Bifidobacterium infantis (1 × 107 CFU/ml), or Lactobacillus salivarius (1 × 107 CFU/ml). CCL20 protein levels in 
cell culture supernatants were measured after 6 hr, 12 hr, or 24 hr as specified on the above graph. Significant levels of CCL20 
were only detected after 12 hr incubation with M. paratuberculosis and after 24 hr with C. difficile. M. smegmatis, B. Infantis and L. 
Salivarius did not result in significant CCL20 secretion at any of the time points or concentrations used. The data are expressed 
as pg/ml CCL20 and represent the mean ± standard error (n = 7 independent experiments). *P < 0.05 relative to untreated 
cells.Page 5 of 13
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Salmonella virulence factor responsible for the induction
of epithelial CCL20 [16], we next examined whether B.
infantis could inhibit IEC responses to Salmonella flagellin.
Confluent HT-29 monolayers were pre-treated with B.
infantis (1 × 105, 1 × 106, or 1 × 107 CFU/ml) for 2 hr, fol-
lowed by 0.5 μg/ml flagellin for 6 hr. Pre-treatment with
B. infantis inhibited flagellin-induced CCL20 secretion in
a dose-dependent manner. At a dose of 1 × 107 CFU/ml B.
infantis this inhibition was significant and was not
dependent on the presence of live bacteria (Fig. 5b).
We next sought to determine whether B. infantis could
limit CCL20 induction by pathogenic bacteria other than
Salmonella. To address this question, we used flagellated
C. difficile and non-flagellated M. paratuberculosis. HT-29
monolayers were pre-treated with live B. infantis or L. sal-
ivarius for 2 hr, followed by treatment with M. paratuber-
culosis for 12 hr or with C. difficile for 24 hr. Pre-treatment
with B. infantis, but not L. salivarius, significantly attenu-
ated CCL20 release in response to both C. difficile bacteria
and their cell-free supernatants by 33.4% or 26.7%,
respectively (Fig. 6). In contrast, pre-treatment with the
bifidobacteria did not modulate M. paratuberculosis
induced CCL20 secretion. Collectively, the data indicate
that B. infantis can restrain CCL20 secretion in response to
flagellin as well as to gram-negative and gram-positive
Intestinal epithelial cells secrete interleukin (IL)-8 differentially in response to various bacteriaFigure 2
Intestinal epithelial cells secrete interleukin (IL)-8 differentially in response to various bacteria. Confluent HT-29 
cells were treated with Salmonella typhimurium (1 × 107 colony-forming units (CFU)/ml), flagellin (0.5 μg/ml), Clostridium difficile 
(1 × 107 CFU/ml), an equal volume of their cell-free culture supernatants, Mycobacterium paratuberculosis (1 × 108CFU/ml), M. 
smegmatis (1 × 108 CFU/ml), Bifidobacterium infantis (1 × 107 CFU/ml), or Lactobacillus salivarius (1 × 107 CFU/ml). IL-8 protein 
levels in cell culture supernatants were measured after 6 hr, 12 hr, or 24 hr as specified by enzyme-linked immunosorbent 
assay. The data are expressed as pg/ml IL-8 and represent the mean ± standard error (n = 7 independent experiments). *P < 
0.05 relative to untreated cells.Page 6 of 13
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non-flagellated bacteria.
Discussion
In the current study, we have demonstrated that HT-29
IECs secrete CCL20 selectively when exposed to various
bacterial species. We show that HT-29 IECs release CCL20
in response to C. difficile, S. typhimurium, M. paratubercu-
losis, or bacterial flagellin, but not to B. infantis,
L. salivarius, or M. smegmatis. This study is the first to dem-
onstrate that a commensal strain can attenuate CCL20
secretion at baseline as well as the levels of CCL20
released following exposure to flagellin and flagellated
enteropathogenic bacteria. To our knowledge, the present
study provides the first evidence that M. paratuberculosis
can induce the secretion of chemokines and activate NF-
κB in HT-29 human IECs. Taken together these data sug-
gest that M. paratuberculosis is potentially pathogenic and
indicate that B. infantis can modulate immune responses
to flagellin and flagellated pathogenic bacteria.
C. difficile and their toxin-containing supernatants have
been shown to stimulate IL-8 production from IECs [37].
However, C. difficile-induced CCL20 secretion has not
been reported previously. Our finding that HT-29 IECs
secrete comparable amounts of CCL20 in response to
both C. difficile bacteria and their supernatants indicates
that components of the supernatant are responsible for
the CCL20 release. Flagellin shed from C. difficile may be
the antigenic factor in the supernatant that elicits the
secretion of CCL20. However, the supernatant represents
Bacterial-induced NF-kB DNA binding activity in intestinal epithelial cellsFigure 3
Bacterial-induced NF-kB DNA binding activity in intestinal epithelial cells. HT-29 cells were untreated, or were 
exposed to Salmonella typhimurium (1 × 107 colony forming units (CFU)/ml), flagellin (0.5 μg/ml), Clostridium difficile (1 × 107 
CFU/ml), or Mycobacterium paratuberculosis (1 × 107 or 1 × 108 CFU/ml) for 1 hr. The DNA binding activity of NF-κB p65 in 
HT-29 nuclear extracts was determined using an enzyme-linked immunosorbent assay-based transcription factor assay. The 
positive control Jurkat nuclear extract provided with the kit was used to verify assay specificity in competition assays with wild-
type or mutated NF-κB oligonucleotides. The data represent the mean absorbance readings ± standard error of five separate 
experiments. P < 0.05 relative to untreated cells.Page 7 of 13
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Bifidobacterium infantis attenuates the baseline secretion of CCL20 in HT-29 cellsFigure 4
Bifidobacterium infantis attenuates the baseline secretion of CCL20 in HT-29 cells. (a) Confluent HT-29 monolayers 
were treated with B. infantis at doses of 1 × 105, 1 × 106, or 1 × 107 colony-forming units/ml, and CCL20 levels were measured 
after 6 hr. B. infantis caused a dose-dependent inhibition of baseline CCL20 secretion by confluent HT-29 monolayers. (b) Con-
fluent HT-29 cells were treated with 1 × 107/ml live B. infantis or L. salivarius, or an equivalent dose of formalin-killed bacteria. 
CCL20 levels were measured after 6 hr. Both live and formalin-killed B. infantis, but not L. salivarius, restrained the baseline 
secretion of CCL20 by HT-29 cells. The data are expressed as CCL20 protein levels relative to untreated control cells and 
represent the mean ± standard error (n = 5 independent experiments). *P < 0.05 compared with untreated monolayers.
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BMC Immunology 2009, 10:54 http://www.biomedcentral.com/1471-2172/10/54Bifidobacterium infantis limits Salmonella typhimurium- and flagellin-induced CCL20 secretionFigure 5 (see previous page)
Bifidobacterium infantis limits Salmonella typhimurium- and flagellin-induced CCL20 secretion. (a) Confluent HT-
29 monolayers were pre-treated for 2 hr with 1 × 107/ml live B. infantis or Lactobacillus salivarius, or an equivalent dose of for-
malin-killed B. infantis prior to infection with S. typhimurium. CCL20 levels were measured 6 hr after infection. Both live and for-
malin-killed B. infantis restrained S. typhimurium induced CCL20 secretion (*P < 0.05 compared with S. typhimurium-infected HT-
29 cells). The data are expressed as pg/ml CCL20 protein and represent the mean ± standard error (n = 8 independent exper-
iments). (b) Confluent HT-29 monolayers were pre-treated for 2 hr with live B. infantis at doses of 1 × 105, 1 × 106, or 1 × 107 
colony-forming units/ml (left panel) or 1 × 107/ml formalin-killed B. infantis (right panel). Subsequently, cells were treated with 
0.5 μg/ml flagellin for 6 hr. Pre-treatment with 1 × 107 live and formalin-killed significantly inhibited flagellin-induced CCL20 
secretion (*P < 0.05 relative to flagellin-treated HT-29 cells). The data are expressed as CCL20 protein levels relative to flagel-
lin-treated cells and represent the mean ± standard error (n = 7 independent experiments).Page 10 of 13
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Bifidobacterium infantis attenuates Clostridium difficile-induced CCL20 secretionFigure 6
Bifidobacterium infantis attenuates Clostridium difficile-induced CCL20 secretion. Confluent HT-29 monolayers 
were pre-treated for 2 hr with 1 × 107 colony-forming units/ml (CFU/ml) live B. infantis or Lactobacillus salivarius prior to infec-
tion with 1 × 107 CFU/ml C. difficile bacteria or an equal volume of their cell-free supernatants, or 1 × 108 CFU/ml Mycobacte-
rium paratuberculosis. CCL20 levels were measured 12 hr or 24 hr post-treatment as indicated. B. infantis, but not L. salivarius, 
restrained C. difficile-induced CCL20 secretion (*P < 0.05 compared with C. difficile- treated HT-29 cells). B. infantis did not limit 
M. paratuberculosis-induced CCL20 secretion. The data are expressed as per cent of pathogen-induced CCL20 secretion and 
represent the mean ± standard error (n = 6 independent experiments).
BMC Immunology 2009, 10:54 http://www.biomedcentral.com/1471-2172/10/54a crude mixture, and the involvement of other compo-
nents such as exotoxins A or B cannot be excluded. Never-
theless, flagellin from Salmonella has been shown
specifically to stimulate CCL20 secretion by IECs [16].
This leads to the recruitment of CCR6-expressing imma-
ture DCs followed by the uptake of flagellated bacteria
and subsequent antigen presentation which initiate adap-
tive immune responses in the gut. TLR5 activation by flag-
ellin has been shown to stimulate epithelial production of
CCL20 and other chemokines like IL-8 [16,17,38]. Flagel-
lin-TLR5 signaling stimulates NF-κB activation to pro-
mote CCL20 expression in models of human intestinal
epithelial cells [39]. We assume that this mechanism is
also responsible for CCL20 expression in our experi-
ments. Recently Muc1 a secreted and membrane bound
mucin protein was shown to serve as a receptor that
bound Pseudomonas aeruginosa and its flagellin, leading to
activation of the MAPK pathway [40]. Muc1 is found in
abundance in HT-29 cells but further examination is war-
ranted in regards to its role in NF-kB and MAPK signalling
[41].
We demonstrate here that B. infantis or L. salivarius do not
elicit CCL20 protein secretion from HT-29 IECs. This
extends our previous finding that IECs display immuno-
logical quiescence when exposed to these commensal bac-
teria [23]. In agreement, it has been shown that other
commensal bacteria including Bifidobacterium bifidum,
Bacteroides vulgatus, and Lactobacillus reuteri are unable to
induce CCL20 mRNA expression in IECs [16,42]. How-
ever, Lactobacillus rhamnosus can augment CCL20 mRNA
and protein expression in human macrophages, but not in
rat uterine epithelial cells [10,43]. Recently, Lactobacillus
rhamnosus GG (LGG) and Lactobacillus casei have been
shown not to induce CCL20 or IL-8 from Caco-2 cells. In
addition, LGG significantly suppressed the expressions of
CCL20 induced by a non-pathogenic flagellated
Escherichia coli or flagellin when cultured simultaneously
[44]. These results are conflicting to our data but reinforce
our belief that different strains from the same bacterial
species can differ in their molecular interactions with the
host.
The mechanism by which B. infantis attenuates CCL20
secretion remains to be investigated. CCL20 has been
shown to act as an anti-bacterial agent secreted apically as
well as basolaterally from IECs. Both secretion apically
and basolaterally can be upregulated in response to a
number of ligands including muramyl dipeptide, a NOD2
ligand [45]. To survive B. infantis could bind or degrade
CCL20. The fact that similar effects are observed using
dead B. infantis renders this hypothesis less likely and we
previously demonstrated that only 10% of B. infantis
remain alive after 2 hr in experimental conditions out-
lined above [23]. The effects of recombinant CCL20 on B.
infantis survival should be assessed.
Another mechanistic explanation would be the downreg-
ulation of expression of TLR5 or associated molecules in
the TLR5 pathway by B. infantis. Detailed characterization
of the TLR5 pathway for example using RNA interference
of TLR5 or downstream MyD88 is warranted and could
demonstrate separate pathways of CCL20 induction for S.
typhimurium and M. paratuberculosis.
It could be argued that the suppression of CCL20 by com-
mensal strains could predispose to a suboptimal inflam-
matory response needed for host defence, especially in the
compromised host. The antibacterial properties of CCL20
on pathogens and commensals alike should also be con-
sidered. B infantis could negate the beneficial antibacte-
rial properties of CCL20. From our previous observations,
B infantis, L. Salivarius and S. typhimurium do not survive
after 6 hr of incubation in experimental conditions out-
lined in our study [23]. Hence we believe that B. infantis
could have more beneficial anti-inflammatory activity
than harmful antibacterial-negating effects. This remains
to be determined in-vivo. The commensal strain Bacter-
oides thetaiotaomicron has been reported to restrict flagel-
lin-mediated signalling also [19]. The responsible
mechanism(s) has not been described, but it is possible
that commensal surface structures engage with host cell
receptors to modulate inflammatory responses [18,46].
The ability of B. infantis and B. thetaiotaomicron to restrain
the signalling induced by flagellin and pathogenic bacte-
ria may limit exaggerated inflammatory responses to the
antigenic burden within the gut and contribute to the
maintenance of mucosal homeostasis. Studies by us and
others have shown that a variety of commensal bacteria
including B. infantis and L. salivarius can suppress IL-8
secretion at baseline and from infected IECs [21-23]. The
anti-inflammatory effects of these commensal bacteria
have been shown to be mediated, at least in part, via NF-
κB [23]. NF-κB transcriptionally regulates both CCL20
and IL-8 [35,36] and a number of mechanisms by which
some commensal bacteria antagonize NF-κB have been
described. These include degradation of the NF-κB inhib-
itor IκB-α, or by the nuclear export of the p65 subunit of
NF-κB in a peroxisome proliferator-activated receptor γ-
dependent manner [19,20].
Our data shows that M. paratuberculosis can activate NF-κB
and induce the secretion of IL-8 and CCL20 from HT-29
human IECs. This would suggest that M. paratuberculosis
may have a role in mediating mucosal damage in the gut.
In ruminants and primates, M. paratuberculosis causes
Johne's disease, a chronic granulomatous enteritis that is
very similar to Crohn's disease in humans [47]. Crohn's
disease is an immune-mediated inflammatory bowel dis-Page 11 of 13
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of environmental, genetic, and immunoregulatory factors
[48]. The possibility that M. paratuberculosis infection may
underlie Crohn's disease has been pursued inconclusively
[49,50], but few studies have investigated whether M.
paratuberculosis can cause mucosal damage in the gut.
Conclusion
In conclusion, we have demonstrated that B. infantis can
attenuate CCL20 secretion in HT-29 IECs; thereby modu-
lating responses to limit inflammatory signals induced by
flagellin and flagellated pathogenic bacteria. Furthermore,
the data demonstrate that M. paratuberculosis activates
immune responses in HT-29 human IECs. We speculate
that M. paratuberculosis may mediate mucosal damage and
that certain commensal bacteria can contribute to the
maintenance of mucosal homeostasis by restraining exag-
gerated inflammatory response to the antigenic burden
within the gut. Similar experiments on different human
IEC lines and ex-vivo IECs would further validate our
results. Future investigations are expected to improve our
understanding of the mechanisms involved in the bacte-
ria-intestinal cell interactions.
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